An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Subscribe To Our Newsletter & Stay Updated
